Jean Lang

7.0k total citations · 1 hit paper
106 papers, 5.4k citations indexed

About

Jean Lang is a scholar working on Public Health, Environmental and Occupational Health, Infectious Diseases and Virology. According to data from OpenAlex, Jean Lang has authored 106 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Public Health, Environmental and Occupational Health, 49 papers in Infectious Diseases and 27 papers in Virology. Recurrent topics in Jean Lang's work include Mosquito-borne diseases and control (53 papers), Viral Infections and Vectors (38 papers) and Rabies epidemiology and control (25 papers). Jean Lang is often cited by papers focused on Mosquito-borne diseases and control (53 papers), Viral Infections and Vectors (38 papers) and Rabies epidemiology and control (25 papers). Jean Lang collaborates with scholars based in France, United States and Thailand. Jean Lang's co-authors include Bruno Guy, Mélanie Saville, Rémi Forrat, Arunee Sabchareon, Pornthep Chanthavanich, Thomas P. Monath, Krisana Pengsaa, Farshad Guirakhoo, Sutee Yoksan and Véronique Barban and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Immunology.

In The Last Decade

Jean Lang

104 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

2012 636 citations Arunee Sabchareon, Kriengsak Limkittikul et al. profile →

Peers

Countries citing papers authored by Jean Lang

Since Specialization

Citations

This map shows the geographic impact of Jean Lang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Lang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Lang more than expected).

Fields of papers citing papers by Jean Lang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Lang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Lang. The network helps show where Jean Lang may publish in the future.

Co-authorship network of co-authors of Jean Lang

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Lang. A scholar is included among the top collaborators of Jean Lang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Lang. Jean Lang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward 2015 ·Vaccine ·Bruno Guy, Olivier Briand, Jean Lang, Mélanie Saville, Nicholas Jackson	120
2	Evaluation of Chimeric Yellow Fever 17D/Dengue Viral Replication in Ticks 2012 ·Vector-Borne and Zoonotic Diseases ·Mária Kazimírová, Nathalie Mantel, (unknown), Mirko Slovák, (unknown), Jean Lang, Bruno Guy, Véronique Barban, Milan Labuda	6
3	Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric Yellow Fever 17D/Dengue viruses 2012 ·Virology ·Véronique Barban, Jorge L. Muñoz‐Jordán, Gilberto A. Santiago, Nathalie Mantel, Yves Girerd-Chambaz, (unknown), Jean‐Baptiste Claude, Jean Lang	28
4	Development of Sanofi Pasteur tetravalent dengue vaccine 2011 ·Americanae (AECID Library) ·Bruno Guy, Mélanie Saville, Jean Lang, João Bosco Siqueira, Lúcia Ferro Bricks	5
5	Decay and Persistence of Maternal Dengue Antibodies among Infants in Bangkok 2011 ·American Journal of Tropical Medicine and Hygiene ·Willem G. van Panhuis, Christine Luxemburger, Krisana Pengsaa, Kriengsak Limkittikul, Arunee Sabchareon, Jean Lang, Anna P. Durbin, Derek A. T. Cummings	22
6	Stability of Yellow Fever Virus under Recombinatory Pressure as Compared with Chikungunya Virus 2011 ·PLoS ONE ·Charles E. McGee, Konstantin A. Tsetsarkin, Bruno Guy, Jean Lang, Kenneth S. Plante, Dana L. Vanlandingham, Stephen Higgs	18
7	Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines 2011 ·Vaccine ·Rosario Z. Capeding, (unknown), (unknown), Socorro Lupisan, Jean Lang, Rémi Forrat, (unknown), Denis Crevat	102
8	Early clinical features of dengue infection in Puerto Rico 2008 ·Transactions of the Royal Society of Tropical Medicine and Hygiene ·Mary M. Ramos, Kay M. Tomashek, D. Fermín Argüello, Christine Luxemburger, (unknown), Jean Lang, Jorge L. Muñoz‐Jordán	36
9	Safety, Viremia and Immunogenicity of Sanofi Pasteur Tetravalent Dengue Vaccine in Adults Previously Exposed to Live, Attenuated Flaviviruses 2008 ·International Journal of Infectious Diseases ·Ming Qiao, (unknown), Rémi Forrat, (unknown), Jean Lang	1
10	Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All 2006 ·Human Vaccines ·Farshad Guirakhoo, Scott Kitchener, Dennis Morrison, Rémi Forrat, Karen McCarthy, Richard Nichols, Sutee Yoksan, Xiaochu Duan, Thomas H. Ermak, Niranjan Kanesa-thasan, Philip Bedford, Jean Lang, Marie‐José Quentin‐Millet, Thomas P. Monath	155
11	High stability of yellow fever 17D-204 vaccine: A 12-year restrospective analysis of large-scale production 2006 ·Vaccine ·Véronique Barban, Yves Girerd-Chambaz, (unknown), (unknown), (unknown), (unknown), B. Barrère, Jean Lang	45
12	Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3) 2006 ·Vaccine ·Violette Sanchez, (unknown), Brian Tomlinson, Paul K.S. Chan, G. Neil Thomas, Rémi Forrat, Laurent Chambonneau, Florence Deauvieau, Jean Lang, Bruno Guy	52
13	Most Highly Exposed Seronegative Men Lack HIV-1-Specific, IFN-γ-Secreting T Cells 2003 ·The Journal of Immunology ·Florian Hladik, Anthony L. Desbien, Jean Lang, Lei Wang, Yan Ding, Sarah Holte, Aaron Wilson, Younong Xu, (unknown), (unknown), M. Juliana McElrath	47
14	Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. 2002 ·American Journal of Tropical Medicine and Hygiene ·Arunee Sabchareon, Jean Lang, Pornthep Chanthavanich, Sutee Yoksan, Rémi Forrat, P. Attanath, C Sirivichayakul, Krisana Pengsaa, Chanathep Pojjaroen‐Anant, Watcharee Chokejindachai, (unknown), (unknown), Natth Bhamarapravati	155
15	Comparison of the immunogenicity and safety of two 17D yellow fever vaccines: results of a randomised equivalence trial in adults 1999 ·UCL Discovery (University College London) ·Jean Lang, JN Zuckerman, P D Clarke, Perry Barrett, C. James Kirkpatrick, Susan C. Wood	0
16	Development of Orphan Vaccines: An Industry Perspective 1999 ·Emerging infectious diseases ·Jean Lang, Susan C. Wood	23
17	Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon. 1999 ·American Journal of Tropical Medicine and Hygiene ·Jean‐Philippe Chippaux, Jean Lang, (unknown), (unknown), (unknown)	52
18	Preclinical Assessment of Immunoreactivity of a New Purified Equine F(ab ′)2 against European Viper Venom 1998 ·Journal of Pharmaceutical Sciences ·(unknown), Charles Lutsch, Jean Lang, Jean‐Michel Scherrmann	13
19	Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres 1997 ·AIDS ·Y Mouton, S. Alfandari, M. Valette, F Cartier, P. Dellamonica, Guy Humbert, Jean Lang, Patrice Massip, D. Méchali, Pascale Leclercq, J Modaï, H. Portier	313
20	Resources and decisions 1975 ·(unknown), Jean Lang	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact